ArticleReviews in urology2007
Newer potential biomarkers in prostate cancer.
Article in Reviews in urology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Pooled it
- Evaluating PSA dynamics for predicting androgen deprivation failure with a patient specific prostate cancer model.NPJ systems biology and applications · 2025Article
- Development and validation of machine learning-based risk prediction models of oral squamous cell carcinoma using salivary autoantibody biomarkers.BMC oral health · 2022Article
- Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing.Medical sciences (Basel, Switzerland) · 2022Review
- Article
- MicroRNAs in prostate cancer: From function to biomarker discovery.Experimental biology and medicine (Maywood, N.J.) · 2018Review
- Identification of four new susceptibility loci for testicular germ cell tumour.Nature communications · 2015Article
- A role for STEAP2 in prostate cancer progression.Clinical & experimental metastasis · 2014Article
- Prostate-specific antigen: any successor in sight?Reviews in urology · 2013Review
- Nanoresonator chip-based RNA sensor strategy for detection of circulating tumor cells: response using PCA3 as a prostate cancer marker.Nanomedicine : nanotechnology, biology, and medicine · 2012Article
- Patented prostate cancer biomarkers.Nature reviews. Urology · 2012Review
- Significance of atypical small acinar proliferation and high-grade prostatic intraepithelial neoplasia in prostate biopsy.Korean journal of urology · 2011Article
- Urine markers and prostate cancer.Central European journal of urology · 2011Review
- Retrospective analysis of prostate cancer recurrence potential with tissue metabolomic profiles.The Prostate · 2010Article
- Challenges in clinical prostate cancer: role of imaging.AJR. American journal of roentgenology · 2009Article
- Endoglin (CD105) as a urinary and serum marker of prostate cancer.International journal of cancer · 2009Article
- The elevated expression of a mismatch repair protein is a predictor for biochemical recurrence after radical prostatectomy.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2009Article
- Evaluation of PCA3 and multiparametric MRI's: collective benefits before deciding initial prostate biopsy for patients with PSA level between 3-10ng/mL.International braz j urol : official journal of the Brazilian Society of UrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate-specific antigen (PSA) screening has led to a significant rise in the number of men diagnosed with prostate cancer and an associated increase in biopsies performed. Despite its limitations, including a positive predictive value of only 25%-40%, PSA remains the only generally accepted biomarker for prostate cancer. There is a need for better tools to not only identify men with prostate cancer, but also to recognize those with potentially lethal disease who will benefit from intervention. A great deal of work has been done worldwide to improve our knowledge of the genetics behind prostate cancer and the specificity of PSA by developing assays for different PSA isoforms. Common genetic alterations in prostate cancer patients have been identified, including CpG hypermethylation of GSPT1 and TMPRSS2:ERG gene fusion. Serum and urine detection of RNA biomarkers (eg, PCA3) and prostate cancer tissue protein antibodies (eg, EPCA) are being evaluated for detection and prognostic tools. This article reviews some of the promising developments in biomarkers.
Indexed as
Identifiers
18231617PMC2204063W168956254What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.